Overall Status

Recruiting (2)

No longer available (1)

Phase

phase 1 (1)

phase 2 (1)

Sponsor

MimiVax, LLC (1)

Pediatric Brain Tumor Consortium (1)

Roswell Park Cancer Institute (1)

Collaborator

Imaging Endpoints (1)

Roswell Park Cancer Institute (1)

Translational Drug Development (1)

Intervention

survaxm (2)

survaxm for patients with non-relapsed dipg post radiation-therapy ages ≥1 and ≤21 years (1)

survaxm for patients with relapsed or progressive mb, hgg or ependymoma ages ≥1 and <10 years (1)

survaxm for patients with relapsed or progressive mb, hgg or ependymoma ages ≥10 and ≤21 years (1)

Study Documents

Intervention Type

biological (2)

drug (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (2)

Expanded Access (1)

SurVaxM

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in Buffalo, New York, Cincinnati (SurVaxM for patients

Recruiting

Medulloblastoma
+7 more

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
+2 more

Buffalo, New York
+2 more

Jul 8, 2022

Newly Diagnosed Glioblastoma Trial in United States (SurVaxM)

Recruiting

Newly Diagnosed Glioblastoma

SurVaxM

San Francisco, California
+9 more

Aug 23, 2022

Glioblastoma Trial (SurVaxM)

No longer available

Glioblastoma

SurVaxM

(no location specified)

Nov 8, 2021